tetano
Editor, Senior Moderator
Infect Disord Drug Targets
. 2022 Feb 18.
doi: 10.2174/1871526522666220218115617. Online ahead of print.
A Review on the New Indication of Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in the Treatment of Coronavirus Disease 2019
Hedyieh Karbasforooshan[SUP] 1 [/SUP], Sofia Salari[SUP] 1 [/SUP], Hesamoddin Hosseinjani[SUP] 1 [/SUP]
Affiliations
Abstract
Background: In December 2019, a recent coronavirus (nCoV) has emerged as a public health concern spreading all around the world. Attempts have been made to discover effective drugs and vaccines. Up to now, multiple COVID-19 vaccines have been developed against this mysterious virus, and crowds of individuals have got vaccinated.
Objective: Anti-viral drugs are effective in treating and managing COVID-19. Nucleoside reverse transcriptase inhibitors (NRTIs) are a collection of antiviral drugs for treating HIV and HBV infections. These drugs prevent virus replication by blocking reverse transcriptase (RT). During this review, we discuss the interaction of this class of anti- HIV drugs with specific functional proteins and enzymes of SARS-CoV-2.
Method: The present search was applied through Web of Science, Embase, PubMed, Scopus, and Google Scholar from commencement to September 2020. The relevant articles about the potential effects of NRTIs on COVID-19 were collected. Finally, twenty-three articles were selected, including all in vitro, in vivo, and clinical studies.
Result: RdRp, spike, ACE2, PNP, inflammatory cytokines, and nucleocapsid protein participate in the pathogenesis of SARS-CoV-2. NRTIs target these proteins through binding to them.
Conclusion: This review is principally focused on the mechanisms of NRTIs to introduce them as potential therapies for COVID-19. However, further in vitro and in vivo investigations will offer helpful information for the identification of drug candidates as a part of COVID-19 management.
Keywords: COVID-19; Coronavirus; Nucleoside reverse transcriptase inhibitors; RdRp; SARS-CoV-2; Zidovudine.
. 2022 Feb 18.
doi: 10.2174/1871526522666220218115617. Online ahead of print.
A Review on the New Indication of Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in the Treatment of Coronavirus Disease 2019
Hedyieh Karbasforooshan[SUP] 1 [/SUP], Sofia Salari[SUP] 1 [/SUP], Hesamoddin Hosseinjani[SUP] 1 [/SUP]
Affiliations
- PMID: 35184718
- DOI: 10.2174/1871526522666220218115617
Abstract
Background: In December 2019, a recent coronavirus (nCoV) has emerged as a public health concern spreading all around the world. Attempts have been made to discover effective drugs and vaccines. Up to now, multiple COVID-19 vaccines have been developed against this mysterious virus, and crowds of individuals have got vaccinated.
Objective: Anti-viral drugs are effective in treating and managing COVID-19. Nucleoside reverse transcriptase inhibitors (NRTIs) are a collection of antiviral drugs for treating HIV and HBV infections. These drugs prevent virus replication by blocking reverse transcriptase (RT). During this review, we discuss the interaction of this class of anti- HIV drugs with specific functional proteins and enzymes of SARS-CoV-2.
Method: The present search was applied through Web of Science, Embase, PubMed, Scopus, and Google Scholar from commencement to September 2020. The relevant articles about the potential effects of NRTIs on COVID-19 were collected. Finally, twenty-three articles were selected, including all in vitro, in vivo, and clinical studies.
Result: RdRp, spike, ACE2, PNP, inflammatory cytokines, and nucleocapsid protein participate in the pathogenesis of SARS-CoV-2. NRTIs target these proteins through binding to them.
Conclusion: This review is principally focused on the mechanisms of NRTIs to introduce them as potential therapies for COVID-19. However, further in vitro and in vivo investigations will offer helpful information for the identification of drug candidates as a part of COVID-19 management.
Keywords: COVID-19; Coronavirus; Nucleoside reverse transcriptase inhibitors; RdRp; SARS-CoV-2; Zidovudine.